Researchers at Jiangsu Hengrui Medicine Co. Ltd., Shanghai Senhui Pharmaceutical Co. Ltd. and Shanghai Shengdi Pharmaceutical Co. Ltd. have disclosed antibody-drug conjugates (ADCs) comprising monoclonal antibodies targeting IL-4R covalently linked to glucocorticoid analogues through a linker. They are reported to be useful for the treatment of asthma and skin allergy.
With a U.S. biotech identified as One Bio, Jiangsu Hengrui Pharmaceutical Co. Ltd. has inked an out-licensing deal potentially worth $1.05 billion for its asthma and chronic sinusitis-targeting drug, SHR-1905. The latest deal gives One Bio exclusive rights to develop, produce and commercialize SHR-1905 worldwide, excluding the greater China territory.
Sichuan Haisco Pharmaceutical Co. Ltd. has identified phosphodiesterase PDE3 and phosphodiesterase PDE4 inhibitors reported to be useful for the treatment of chronic obstructive pulmonary disease (COPD) and asthma.
With a U.S. biotech identified as One Bio, Jiangsu Hengrui Pharmaceutical Co. Ltd. has inked an out-licensing deal potentially worth $1.05 billion for its asthma and chronic sinusitis-targeting drug, SHR-1905. The latest deal gives One Bio exclusive rights to develop, produce and commercialize SHR-1905 worldwide, excluding the greater China territory.
Less than two years ago, in October 2021, a group of investors bid at auction on a promising monoclonal antibody to treat asthma, chronic rhinosinusitis and other inflammatory conditions, winning the asset known as UPB-101, the sole focus of the then-newly launched Upstream Bio Inc.
Glucocorticoids are very effective immunosuppressive and anti-inflammatory drugs that cause dose-limiting toxicities in brain, liver and bone preventing their use mainly in chronic disorders. Researchers from Immunext Inc. recently reported results from the therapeutic evaluation of the nontoxic glucocorticoid INX-200 with anti-inflammatory efficacy in a once-per-month injection.
Researchers at Academia Sinica, CSIC (Consejo Superior de Investigaciones Cientificas) and Universidad de Sevilla have divulged 5-aminohexahydro-6,7,8-trihydroxy-3h-oxazolo[3,4-a]pyridin-3-one derivatives acting as Toll-like receptor 4 (TLR4; CD284) antagonists or TLR4 agonists reported to be useful for the treatment of autoimmune disease, metabolic syndrome, asthma, inflammatory bowel disease, allergic rhinitis, nonalcoholic steatohepatitis, atherosclerosis and infections, among others, and also as vaccine adjuvants.
PARP14 is an ADP-ribosyltransferase that transfers ADP-ribose from NAD+ onto the appropriate protein target. PARP14 selectively binds to STAT6 and promotes expression of IL-4-regulated genes, thus modulating inflammatory signaling pathways. PARP14 is overexpressed in tissues from patients with dermatomyositis, atopic dermatitis, psoriasis and other inflammatory disorder cells compared to normal tissues.
Mast cell-expressed membrane protein 1 (MCEMP1) is a type II transmembrane protein predominantly expressed in myeloid lineage immune cells, including lung-resident mast cells and alveolar macrophages. MCEMP1 is a critical factor in allergic and inflammatory lung diseases, with higher expression levels correlating with increased disease severity. However, the molecular mechanisms underlying the role of MCEMP1 in the pathogenesis of lung inflammatory diseases remain unclear.
Visionhealth GmbH will use the €3 million (US$3.2 million) it recently raised in a pre-series A financing to conduct a clinical trial on its digital health app designed to provide more accurate dosing of treatments for chronic obstructive pulmonary disease (COPD) and asthma.
